West Pharmaceutical Services, Inc. (WST)

Basic

  • Market Cap

    $25.95B

  • EV

    $25.36B

  • Shares Out

    73.99M

  • Revenue

    $2,926.5M

  • Employees

    10,700

Margins

  • Gross

    38.04%

  • EBITDA

    30.09%

  • Operating

    25.56%

  • Pre-Tax

    23.1%

  • Net

    19.11%

  • FCF

    14.35%

Returns (5Yr Avg)

  • ROA

    11.3%

  • ROE

    21.37%

  • ROCE

    21.58%

  • ROIC

    22.48%

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • EV/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    $372.19

  • P/E

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • EV/FCF

    —

Per Share

  • Rev

    $39.33

  • Earnings (Dil)

    $7.42

  • FCF

    $5.56

  • Book Value

    $38.76

Growth (CAGR)

  • Rev 3Yr

    12.83%

  • Rev 5Yr

    11.34%

  • Rev 10Yr

    8.07%

  • Dil EPS 3Yr

    21.56%

  • Dil EPS 5Yr

    29.36%

  • Dil EPS 10Yr

    16.93%

  • Rev Fwd 2Yr

    5.59%

  • EBITDA Fwd 2Yr

    3.34%

  • EPS Fwd 2Yr

    1.23%

  • EPS LT Growth Est

    7.83%

Dividends

  • Yield

    —

  • Payout

    10.11%

  • DPS

    $0.76

  • DPS Growth 3Yr

    5.9%

  • DPS Growth 5Yr

    6.3%

  • DPS Growth 10Yr

    7.18%

  • DPS Growth Fwd 2Yr

    15.55%

Select a metric from the list below to chart it

Dec '13
Dec '15
Dec '17
Dec '19
Dec '21
LTM
Metric
Dec '13
Dec '14
Dec '15
Dec '16
Dec '17
Dec '18
Dec '19
Dec '20
Dec '21
Dec '22
LTM

Total Revenues

1,717.4

1,839.9

2,146.9

2,831.6

2,886.9

2,926.5

Total Revenues % Chg.

7.4%

7.1%

16.7%

31.9%

2.0%

0.6%

Cost of Goods Sold, Total

1,172.0

1,234.2

1,379.1

1,653.9

1,750.7

1,813.3

Gross Profit

545.4

605.7

767.8

1,177.7

1,136.2

1,113.2

Selling General & Admin Expenses, Total

256.2

272.8

300.8

358.1

316.0

299.0

Stock-Based Compensation

—

—

—

—

—

—

R&D Expenses

40.3

38.9

46.9

52.8

58.5

65.9

Other Operating Expenses

-2.0

-2.0

-2.5

—

-2.1

0.2

Other Operating Expenses, Total

294.5

309.7

345.2

410.9

372.4

365.1

Operating Income

250.9

296.0

422.6

766.8

763.8

748.1

Interest Expense, Total

-8.4

-8.5

-8.2

-8.2

-7.9

-9.5

Interest And Investment Income

2.1

3.8

1.4

1.0

5.1

21.5

Net Interest Expenses

-6.3

-4.7

-6.8

-7.2

-2.8

12.0

Income (Loss) On Equity Invest.

7.6

8.9

17.4

20.1

20.7

17.6

Currency Exchange Gains (Loss)

5.5

4.6

1.5

1.4

4.1

-3.5

EBT, Excl. Unusual Items

257.7

304.8

434.7

781.1

785.8

774.2

Restructuring Charges

-8.0

-3.0

-4.6

-2.2

-23.8

-24.7

Gain (Loss) On Sale Of Investments

—

—

-2.5

-4.3

-3.5

-3.5

Gain (Loss) On Sale Of Assets

—

—

—

—

—

-11.6

Asset Writedown

-2.9

-2.7

-7.7

-4.1

-2.7

-8.0

Legal Settlements

—

4.7

—

—

—

3.8

Other Unusual Items

1.5

-3.1

-1.2

-1.5

-55.2

-54.1

EBT, Incl. Unusual Items

248.3

300.7

418.7

769.0

700.6

676.1

Income Tax Expense

41.4

59.0

72.5

107.2

114.7

116.7

Earnings From Continuing Operations

206.9

241.7

346.2

661.8

585.9

559.4

Net Income

206.9

241.7

346.2

661.8

585.9

559.4

Net Income to Common Incl Extra Items

206.9

241.7

346.2

661.8

585.9

559.4

Net Income to Common Excl. Extra Items

206.9

241.7

346.2

661.8

585.9

559.4

Total Shares Outstanding

74.1

74.1

74.0

74.2

74.1

74.0

Weighted Avg. Shares Outstanding

73.9

74.0

73.9

74.4

74.4

74.4

Weighted Avg. Shares Outstanding Dil

75.4

75.4

75.8

76.3

75.8

75.5

EPS

2.8

3.3

4.7

8.9

7.9

7.5

EPS Diluted

2.7

3.2

4.6

8.7

7.7

7.4

EBITDA

355.3

399.4

531.7

889.1

884.4

880.6